ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

JNP Juniper Pharmaceuticals, Inc. (delisted)

11.50
0.00 (0.00%)
27 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Juniper Pharmaceuticals, Inc. (delisted) NASDAQ:JNP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.50 11.45 11.60 0 00:00:00

Juniper Pharmaceuticals to Report First Quarter 2018 Results on May 10, 2018

01/05/2018 12:00pm

PR Newswire (US)


Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart


From Nov 2019 to Nov 2024

Click Here for more Juniper Pharmaceuticals, Inc. Charts.

BOSTON, May 1, 2018 /PRNewswire/ -- Juniper Pharmaceuticals (Nasdaq:JNP) ("Juniper" or the "Company"), will hold a conference call on May 10, 2018, to discuss the financial results for the first quarter ended March 31, 2018, as follows:

Date:                  

May 10, 2018



Time:                 

8:30 a.m. EST



Dial-in numbers:   

Toll free: (1-866-374-4635) (U.S.), (1-855-669-9657) (Canada), or




International: (1-412-902-4218)

Audio webcast (live & archive): www.juniperpharma.com, under 'Investors' or click here.

The teleconference replay will be available approximately one hour after completion through Thursday, March 15, 2018, at 1-877-344-7529 (U.S.), 1-855-669-9658 (Canada) or 1-412-317-0088 (International). The replay access code is 10119657.

The archived webcast will be available for one year via the aforementioned URLs.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc.'s core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. Please visit www.juniperpharma.com for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.

Investor Contact:  
Laura Perry or Heather Savelle
Argot Partners 
212-600-1902
laura@argotpartners.com 
heather@argotpartners.com

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.  
Follow us on
LinkedIn  

 

Juniper Pharmaceuticals, Inc.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-first-quarter-2018-results-on-may-10-2018-300639511.html

SOURCE Juniper Pharmaceuticals, Inc.

Copyright 2018 PR Newswire

1 Year Juniper Pharmaceuticals, Inc. Chart

1 Year Juniper Pharmaceuticals, Inc. Chart

1 Month Juniper Pharmaceuticals, Inc. Chart

1 Month Juniper Pharmaceuticals, Inc. Chart